Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (vol 21, 391, 2020)

Open Access
Publisher Website
Google Scholar
Abstract
An amendment to this paper has been published and can be accessed via the original article.